Skip to main content

Genetic Technologies Issues $5M Convertible Note to Ironridge

NEW YORK (GenomeWeb News) – Genetic Technologies said yesterday that it has issued a $5 million redeemable convertible note to Ironridge BioPharma, a division of institutional investor Ironridge Global IV, Ltd.

The Melbourne, Australia-based molecular diagnostics firm said that it as received A$5.6 million (US$5 million) from Ironridge in exchange for the note. The firm previously said that the notes issued to Ironridge would be convertible into new Nasdaq-traded American Depository Receipts at a fixed price of US$3.00 per ADR.

In Tuesday morning trade on the Nasdaq, Genetic Technologies' ADRs were trading up nearly 3 percent at US$1.59.

"The funds raised from the note, together with the net proceeds from the recently completed private placement and share purchase plan, adequately position the company with resources necessary to expand its US operations and continue the growth of its flagship test Brevagen," Genetic Technologies Chairman Mal Brandon said in a statement. "In addition, the funds will be used to complete studies that will add new ethnicities to increase the size of the available market and improve reimbursement performance."

Brevagen is the firm's flagship non-familial breast cancer risk assessment test.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.